Brokerages Set Fate Therapeutics (FATE) Target Price at $16.17
Fate Therapeutics (NASDAQ:FATE) has received an average recommendation of “Buy” from the eleven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $16.17.
A number of equities research analysts recently weighed in on the company. Zacks Investment Research upgraded Fate Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price target on the stock in a research note on Friday, January 19th. Wedbush restated an “outperform” rating and issued a $19.00 price target on shares of Fate Therapeutics in a research note on Thursday, March 29th. BidaskClub upgraded Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. UBS cut Fate Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 6th. Finally, HC Wainwright reiterated a “hold” rating and set a $12.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, March 20th.
FATE opened at $11.15 on Friday. Fate Therapeutics has a 1-year low of $2.52 and a 1-year high of $14.45. The company has a debt-to-equity ratio of 0.19, a current ratio of 9.29 and a quick ratio of 9.29.
A number of hedge funds have recently bought and sold shares of FATE. Raymond James & Associates bought a new position in Fate Therapeutics during the 4th quarter worth $141,000. The Manufacturers Life Insurance Company increased its position in Fate Therapeutics by 61.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 33,337 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 12,686 shares during the period. California State Teachers Retirement System bought a new position in Fate Therapeutics during the 2nd quarter worth $219,000. Russell Investments Group Ltd. bought a new position in Fate Therapeutics during the 3rd quarter worth $234,000. Finally, Two Sigma Advisers LP increased its position in Fate Therapeutics by 257.0% during the 4th quarter. Two Sigma Advisers LP now owns 71,400 shares of the biopharmaceutical company’s stock worth $436,000 after buying an additional 51,400 shares during the period. Hedge funds and other institutional investors own 66.41% of the company’s stock.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.